Sangart Inc.
This article was originally published in Start Up
Executive Summary
Sangart Inc. says it is the first company to thoroughly understand the mechanisms of cell-free hemoglobin in the body and has designed Hemospan to mimic the size and behavior of natural hemoglobin. Sangart believes that its science and simplified production method put it on track to create a safe, cost-effective, commercially viable hemoglobin-based oxygen carrier.
You may also be interested in...
Artificial Blood: Finding the Formula for Approval
Despite decades of effort and more than $1 billion dollars invested in commercial blood substitute R&D, no products are approved for use in the US. Can next-generation companies succeed where so many others have failed?
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)